4501744 Substituted-aza-cytosine compounds and anti-viral uses thereof

1
PATENT A method for determining a member of a specific binding pair-ligand and receptor (anti- ligand). Reagents employed include a first modified member which provides an electrical field due to the presence of a plurality of ionic charges and a second modified member labeled with a component of a signal producing system, which system may have one or more compo- nents. The average proximity in the assay medium of the first and second modified mem- bers is related to the amount of analyte, where the observed signal from the signal producing system is related to the effect of the electrical field on the signal producing system. Also, com- positions are provided, as well as reagents, in predetermined ratios for optimizing the signal response to variations in analyte concentration. ABSTRACTS 4501744 127 SUBSTITUTED-AZA-CYTOSINE COMPOUNDS AND ANTI-VIRAL USES THEREOF Kelvin K Ogilvie, Candiac, Canada assigned to ens BIO LOGICALS Inc Nucleoside analogues having a ring-open struc- ture, of general formula: See Patent for Chemical Structure where R and R' may be hydrogen, silyl groups, substituted alkyl groups, benzyl groups and the like, and X is an optionally substituted pyrimidine or triazine base, exhibit anti-viral ac- tivities e.g. against herpes simplex virus and cytomegalo-virus at non-toxic levels. 4501693 METHOD OF PREPARING IMMUNOSTIMULANT PROTEOGLYCANS WHICH INDUCE PRODUCTION OF INTERFERON, PROTEOGLYCANS OBTAINED AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM d'Hinterland Lucien Dussourd, Gerard Nor- mier, Anne-Marie Pinel, Castres, France as- signed to Pierre Fabre S A The present invention relates to a method of pre- paring bacterial membranous proteoglycans with an action which induces interferon from soluble membranous proteoglycans of a strain of gram-negative bacterium, wherein the soluble membranous proteoglycans of a strain of gram- negative bacterium are hydrolyzed by lysozyme and the proteoglycans with a molecular weight between 200,000 and 400,000 are separated from the hydrolysis product. The products obtained are useful as a medicament. 4503030 DEVICE FOR DELIVERING DRUG TO CERTAIN PH ENVIRONMENTS David Edgren, Patrick S L Wong, Felix Theeuwes assigned to ALZA Corporation An osmotic device is disclosed for delivering a beneficial agent to a first environment having a pH of 1.0 to 3.5 inclusive and to a second en- vironment having a pH of greater than 3.5 to 8.0. The device maintains its integrity in the first en- vironment and loses its integrity in the second environment. L × QD I T" "7" x -'b'~ 4501728 MASKING OF LIPOSOMES FROM RES RECOGNITION W Blair Geho, John R Lau assigned to Tech- nology Unlimited Inc A biochemical membrane covered with sialic residues thereby provides a coating that masks the surface membrane from recognition and removal by the scavenging RES cells of the body. 4503035 PROTEIN PURIFICATION PROCESS AND PRODUCT Sidney Pestka, Menache Rubinstein assigned to Hoffmann-La Roche Inc An improved process for purifying proteins, particularly proteins having molecular weights in excess of 12,000 involves novel applications of high performance liquid chromatography on a

Transcript of 4501744 Substituted-aza-cytosine compounds and anti-viral uses thereof

PATENT

A method for determining a member of a specific binding pair-ligand and receptor (anti- ligand). Reagents employed include a first modified member which provides an electrical field due to the presence of a plurality of ionic charges and a second modified member labeled with a component of a signal producing system, which system may have one or more compo- nents. The average proximity in the assay medium of the first and second modified mem- bers is related to the amount of analyte, where the observed signal from the signal producing system is related to the effect of the electrical field on the signal producing system. Also, com- positions are provided, as well as reagents, in predetermined ratios for optimizing the signal response to variations in analyte concentration.

ABSTRACTS

4501744

127

S U B S T I T U T E D - A Z A - C Y T O S I N E C O M P O U N D S A N D A N T I - V I R A L

U S E S T H E R E O F

Kelvin K Ogilvie, Candiac, Canada assigned to ens BIO LOGICALS Inc

Nucleoside analogues having a ring-open struc- ture, of general formula: See Patent for Chemical Structure where R and R' may be hydrogen, silyl groups, substituted alkyl groups, benzyl groups and the like, and X is an optionally substituted pyrimidine or triazine base, exhibit anti-viral ac- tivities e.g. against herpes simplex virus and cytomegalo-virus at non-toxic levels.

4501693

M E T H O D O F P R E P A R I N G I M M U N O S T I M U L A N T

P R O T E O G L Y C A N S W H I C H I N D U C E P R O D U C T I O N O F

I N T E R F E R O N , P R O T E O G L Y C A N S O B T A I N E D A N D

P H A R M A C E U T I C A L C O M P O S I T I O N S C O N T A I N I N G

T H E M

d'Hinterland Lucien Dussourd, Gerard Nor- mier, Anne-Marie Pinel, Castres, France as- signed to Pierre Fabre S A

The present invention relates to a method of pre- paring bacterial membranous proteoglycans with an action which induces interferon from soluble membranous proteoglycans of a strain of gram-negative bacterium, wherein the soluble membranous proteoglycans of a strain of gram- negative bacterium are hydrolyzed by lysozyme and the proteoglycans with a molecular weight between 200,000 and 400,000 are separated from the hydrolysis product. The products obtained are useful as a medicament.

4503030

D E V I C E F O R D E L I V E R I N G D R U G T O C E R T A I N P H E N V I R O N M E N T S

David Edgren, Patrick S L Wong, Felix Theeuwes assigned to ALZA Corporation

An osmotic device is disclosed for delivering a beneficial agent to a first environment having a pH of 1.0 to 3.5 inclusive and to a second en- vironment having a pH of greater than 3.5 to 8.0. The device maintains its integrity in the first en- vironment and loses its integrity in the second environment.

L × QD I T" "7" x -'b'~

4501728

M A S K I N G O F L I P O S O M E S F R O M R E S R E C O G N I T I O N

W Blair Geho, John R Lau assigned to Tech- nology Unlimited Inc

A biochemical membrane covered with sialic residues thereby provides a coating that masks the surface membrane from recognition and removal by the scavenging RES cells of the body.

4503035

P R O T E I N P U R I F I C A T I O N P R O C E S S A N D P R O D U C T

Sidney Pestka, Menache Rubinstein assigned to Hoffmann-La Roche Inc

An improved process for purifying proteins, particularly proteins having molecular weights in excess of 12,000 involves novel applications of high performance liquid chromatography on a